TP53 and acute myeloid leukemia: Importantly, this TP53 mutation was undetectable in the pre-BMT sample and was barely detectable (~0.2% VAF) in the post-BMT sample, but it was greatly increased (~9% VAF) in the relapsed-AML sample (Table 4 and Fig. 1B).